Publication | Closed Access

Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age

Primary ImmunodeficiencyAllergyAutoimmune DiseaseImmunodeficienciesImmunologyHealthy Indian ChildrenPhase Ii StudyAutoimmunityImmunologic DiseaseImmunotherapyMedicineInborn Error Of Immunity